secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2026-08-11T20:06:14+00:00
Accession:  0001672688-26-000134
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci reports positive interim Phase 1 data for ABS-201; completes $100M offering
--------------------------------------------------------------------------------

- Positive interim Phase 1 data for ABS-201: well tolerated, half-life ≥65 days, supports 2-3 doses/6 months.
- Completed $100M underwritten offering incl. $40M strategic investment from Eli Lilly; net proceeds $93.6M.
- Cash and securities $201.1M at 6/30/26, up from $125.7M at 3/31/26; runway into H2 2028.
- Q2 2026: revenue $0.3M (vs $0.6M YoY); net loss $33.2M (vs $30.6M YoY).
- ABS-201 endometriosis Phase 2 planned Q4 2026; PHL proof-of-concept data H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/0001672688-26-000134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/absc-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001672688-26-000134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer